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Background: TPI 1020 is a novel compound with potential for anti-neutrophil effects. TPI 1020
exerts its effects by a dual mechanism of action involving corticosteroid activity and controlled
donation of nitric oxide.
Objectives: We assessed the safety, pharmacodynamic and pharmacokinetic activity of
ascending doses of TPI 1020 compared to budesonide in asthma.coring system; AUC, area under the curve; BUN, blood urea nitrogen; CBC, complete blood counts;
, chronic obstructive pulmonary disease; CRP, C-reactive protein; ECG, electrocardiograms; eNO,
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tration that causes a 20% fall; PD, pharmacodynamic; PK, pharmacokinetic; ppm, parts per million;
D, standard deviation; SE, standard error; SEM, standard error of the mean; Tmax, time at maximal
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1160 L.-P. Boulet et al.Methods: Smokers with mild asthma (nZ 27) were randomized to receive either 600 mcg of
TPI 1020 (nZ 13) or 400 mcg of budesonide (nZ 14) bid for 2 weeks followed by 1200 and
800 mcg bid, respectively, for an additional week.
Result: There was no serious adverse event and all but one adverse event were mild or
moderate (severe headache with budesonide). Patients receiving TPI 1020 reported three-fold
fewer treatment-emergent AEs (nZ 13) than those receiving budesonide (nZ 39). TPI 1020
had similar effects as budesonide on FEV1, PEF, rescue medication, asthma scoring system,
methacholine response, sputum eosinophils and exhaled NO. Sputum neutrophils (%) tended
to decrease more with TPI 1020 (32.6% decrease versus 3.7% increase for budesonide); the
decrease occurring only in patients with high neutrophils at baseline. A significant difference
favoring TPI 1020 was noted for CRP. Budesonide caused a statistically significant decrease in
24 h urinary free cortisol over 22 days (median of 4.4e2.8 mcg/ml, pZ 0.01) whereas TPI 1020
had no such effect (4.4e5.8 mcg/ml), suggesting lower systemic corticosteroid exposure
following TPI 1020 treatment.
Conclusion: TPI 1020 appears safe in asthmatic smokers and warrants further investigation in
respiratory conditions.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Bronchial asthma is widely recognized as a complex chronic
inflammatory disorder of the airways characterized by
acute episodes of airway obstruction, increased airways
responsiveness and occasionally reduced pulmonary func-
tion.1 In this disease exhaled nitric oxide (eNO) is increased
when compared to normal individuals and eNO decreases
when asthma improves.2,3 A discrepancy exists between the
association of a decrease in eNO when asthma improves and
the potential benefits of NO on inflammation and bron-
choconstriction. Indeed, inhaled NO may be beneficial by
reducing inflammatory cell adhesion and infiltration into
the airways4 as well as by promoting bronchodilation.5
Ho¨gman et al.6 demonstrated improved specific airway
conductance after the inhalation of 80 parts per million
(ppm) of NO in non-smoking subjects with hyperreactive
airways and in individuals with a clinical diagnosis of
asthma who were being maintained on short-acting b2
agonists and inhaled corticosteroids. Whether adminis-
tering NO to patients with asthma that are receiving
inhaled corticosteroids over a longer period of time is
beneficial has not been studied.
TPI 1020 is a novel anti-inflammatory compound that is
enzymatically cleaved in vivo to yield an NO donor and
budesonide, most likely by esterases in the lung.7 Non-
clinical pharmacological studies have provided evidence
that TPI 1020 may be effective in treating chronic
obstructive pulmonary disease (COPD) and other respira-
tory diseases in humans where neutrophils are involved in
the pathophysiology of the disease.8 Interestingly,
neutrophils seem to play a role in various phenotypes of
asthma and have been shown to be increased in the
sputum of smokers with asthma.9 The objectives of this
study was to determine the safety, pharmacodynamic
(PD) and pharmacokinetic (PK) activity of multiple doses
of inhaled TPI 1020 compared to that of equimolar doses
of inhaled budesonide in subjects with mild asthma who
smoke. We chose patients with asthma who smoke since
these patients were reported to have not only an
increase in neutrophils within their sputum,9 as describedin COPD but also a reduced response to inhaled
corticosteroids.
Methods
Subjects and study design
This was a randomized (1:1), multi-center double-blind
escalated-dose study. Individuals between 18 and 65 years
old with stable, mild asthma by American Thoracic Society
(ATS) criteria,10 with a smoking history of 5e25 pack/years
and continuing to smoke despite medical advice were
eligible for enrolment. Subjects had not taken inhaled
corticosteroids for at least 1 month. Forced expiratory flow
in 1 s (FEV1) must have been 75% of predicted value at
least 4 h following use of rescue medication salbutamol and
show significant reversibility (12% and at least 200 mL
after inhalation of salbutamol 200e400 mg during screening
or within the last 6 months) or a positive methacholine
challenge test as shown by a provocative concentration of
methacholine (PC20) 16 mg/mL within the last 5 years or
a spontaneous fluctuation of FEV1 20% within the last
5 years.
Subjects who met the inclusion/exclusion criteria
entered a 14-day run-in period with only a b-agonist bron-
chodilator (inhaled salbutamol) to use as needed. Subjects
entered the therapeutic part of the study if they had a total
symptom assessment score 2 and <6 on at least 3 days of
the last 7 days of the run-in period or a peak expiratory flow
(PEF) diurnal variation >15% and <30% on at least 3 days of
the last 7 days of the run-in period in addition to a urine
cotinine level 200 ng/mL at the screening visit, indicative
of active smoking.
Those subjects who completed the 14-day run-in period
were assigned to receive either inhaled TPI 1020 or
budesonide over a 21-day period. Since TPI 1020 is 1.4
times heavier than budesonide on a ‘budesonide’ molar
basis, the doses administered were as follows: budesonide
400 mg bid for 14 days then 800 mg bid for 7 days; TPI 1020:
600 mg bid for 14 days then 1200 mg bid for 7 days. Study
treatments were delivered in lactose-based blends using
Table 1 Subject demographics.
Budesonide (SE) TPI 1020 (SE)
Age (years) 34.7 (2.6) 34 (3.1)
Sex (M/F) 7/7 7/6
FEV1 (L) 3.3 (0.8) 3.0 (0.5)
FEV1% pred. 87.4 (11) 83.2 (8.9)
PEF AM (L/min) 414.8 (25) 365.1 (26)
Rescue free days (%) 40.7 (11) 39 (11)
PC20 (mg/ml) 1.4 (1.3) 3.5 (5.7)
Pack/years 12.3 (1.8) 9.3 (1.5)
Cigarettes/day 12.8 (1.3) 12.4 (1.3)
Urine cotinine (ng/ml) 1663 (240) 1059 (182)
SE, standard error; M, male; F, female; FEV1%, forced expiratory
volume in 1 s; PEF AM, peak expiratory flow in the morning;
PC20, provocative concentration that causes a 20% fall. pZ NS
between both groups for all values.
Safety PK and PD of TPI 1020 in Smokers with Asthma 1161the capsule-based Aeroliser dry powder inhaler. Budeso-
nide capsules (Miflonide, Novartis Pharmaceuticals)
delivered 383 mg as compared to 423 mg of budesonide for
TPI 1020 (equivalent to 9.5% more budesonide delivered to
the body in the TPI 1020 group). However, the fine particle
dose (<5 microns) of budesonide was 104 mg for the
budesonide capsules and only 78 mg for the TPI 1020
capsules (equivalent to 25% less budesonide delivered to
the lung in the TPI 1020 group). No other asthma medi-
cation, except rescue salbutamol, was permitted during
the study.
Safety parameters
Safety parameters consisted of adverse events and serious
adverse events, vital signs, asthma symptoms, laboratory
determinations of complete blood counts (CBC), urinalysis,
regular blood biochemistry, plasma C-reactive protein
(CRP), plasma and urinary free cortisol levels, spirometry
and electrocardiograms (ECGs). The asthma control scoring
system questionnaire11 (ACSS) was also used as a safety
parameter. The ACSS questionnaire is made of three
sections; a clinical score, the physiological score and the
inflammation score. It was decided that for the physiolog-
ical section of the questionnaire, the more informative
FEV1 would be preferred for assessment over the PEF or the
diurnal fluctuation. The plasma pharmacokinetics (PK)
profile of TPI 1020 and of budesonide was also determined
on days 1 and 14 for up to 8 h after a dose in a sub-group of
8 to 10 patients per group.
Exploratory assessment of efficacy
Although this study was only powered to determine signif-
icant changes of the medication on neutrophils, the
following parameters were also evaluated: sputum total
cell and differential cell counts12 on days 0, 15 and 22, pre-
dose FEV1 measurements on days 0, 1, 14, 15 and 22, PEF
measured with a Mini-Wright peak flow meter throughout
the study, use of daily rescue medication (salbutamol)
throughout the study, the response to methacholine chal-
lenge test13 and the eNO levels (chemiluminescence after
reaction with ozone) on days 0, 15 and 22 and plasma CRP
levels on days 0, 15 and 22. Effects on FEV1 over 8 h on days
1 and 14 were evaluated in a sub-group of 8 to 10 patients
per group.
Determination of sample size
The sample size was chosen to provide information about
safety, the primary study objective, and with the power to
detect a 20% difference in the decrease in sputum
neutrophils with TPI 1020 compared with budesonide.
There were no published studies in mild smokers with
asthma that had described the variability in sputum
neutrophils. However, based on the publication by Gamble
et al.,14 almost all patients with COPD had increased
sputum neutrophils (>20%) and we then, by comparison
with these data, calculated that if 13 subjects per group
completed the study, a difference of 20% in neutrophils (%)
between groups could be detected with a power of 80%.Statistical analysis
The methods of analysis used to compare both treatment
arms included Students t-test, Chi2 test or Fisher exact test
as appropriate for each variable. All tests of hypotheses
were two-sided with statistical significance defined as
p  0.05. Tests of normality were conducted for continuous
variables, and as a result, the Wilcoxon rank sum test was
used. Data are presented as mean  standard error of the
mean (SEM) unless otherwise noted. When data were not
normally distributed, the results are presented as medians.
Results
Subject demographics
A total of 27 subjects were enrolled into the study: 13 in the
TPI 1020 and 14 in the budesonide treatment group. One
subject in the budesonide group withdrew, prior to
receiving medication, resulting in 13 subjects in each group
in the intent-to-treat population. Eight subjects in the TPI
1020 and 10 subjects in the budesonide group underwent PK
and PD evaluations. All 26 subjects completed the study.
Characteristics of the patients in the two groups were not
significantly different, although FEV1, peak flow and
sputum neutrophils tended to be lower, and eNO and
sputum eosinophils tended to be higher in the TPI 1020-
treated group (see Tables 1 and 2B). There were also no
differences between groups in hematology, chemistry,
urine and ECG.
Safety
There was no serious adverse event during the study and
only one severe adverse event (headache in a budesonide-
treated patient). There was no difference in the number of
subjects that reported adverse events between TPI 1020
(nZ 6) and budesonide (nZ 7). However, there were
three-fold less total treatment-emergent adverse events in
the TPI 1020-treated patients when compared to budeso-
nide [13 versus 39 (see Fig. 1)]. The TPI 1020 AEs were:
upper abdominal pain (2), headache (2), chest pain (1),
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Figure 1 Adverse events reported by patients of each group.
The total number of either ‘treatment-emergent’ (occurring
while patients were receiving either TPI 1020 or budesonide) or
physician-determined ‘drug-related’ adverse events during the
21-day therapeutic period is presented for Budesonide (open
bars) or TPI 1020 (solid bars).
1162 L.-P. Boulet et al.muscle spasm (1), insomnia (1), ear discomfort (1), infec-
tive conjunctivitis (1), UTI (1), C-Reactive protein increased
(1), dyspnea (1), excoriation (1), and lymphadenopathy (1).
There were also less drug-related adverse events in TPI
1020-treated patients (6 versus 9).
Treatment with neither medication had any effect on
standard parameters of hematology, chemistry and urine
except for blood urea nitrogen (BUN). BUN increased
significantly in the budesonide-treated group from 4.2
(baseline) to 5.2 and 5.3 mmol/L on days 15 and 22,
respectively (p < 0.05 for both time points). BUN did not
change in the TPI 1020-treated group (4.4, 3.9 and
4.4 mmol/L on days 0, 15 and 22, respectively). Neither
treatment had any effect on the ECG, the QT and the QTc
interval recorded in the PD group 20, 45 min, 3 and 8 h post
dose on day 1, after the first dose, and on day 14.
Both therapies also had no significant effects on morning
plasma cortisol level (budesonide 13.1, 10.9 and 11.4 mcg/
dl and TPI 1020 13.7, 14.5 and 11.7 mcg/dl at baseline, days
15 and 22, respectively). However, budesonide significantly
decreased 24 h urinary free cortisol whereas TPI 1020 had
no such effect (see Fig. 2).BUDESONIDE
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Figure 2 Effects of budesonide or TPI 1020 on urinary cortisol. T
cortisol are presented. Median values for budesonide are 4.6 at da
0 is 4.4, and 5.8 at day 22 (pZ 0.014 TPI 1020 versus budesonide)Effects on sputum neutrophils and other cells
A trend was found for a decrease in sputum neutrophils in
the TPI 1020 group (see Fig. 3). Median sputum neutrophils
changed from 39.6 to 41.1% in the budesonide group (3.7%
increase) and from 29.8 to 20.1% in the TPI 1020 group
(32.6% decrease). Since there was an unexpectedly large
number of patients with normal baseline neutrophils in the
sputum (9 of 26 patients with neutrophils <20%), a post hoc
analysis was performed in patients with baseline sputum
neutrophils >20% (abnormal) and those with sputum
neutrophils <20% (normal). In those patients with high
neutrophils at baseline, budesonide decreased sputum
neutrophils from a mean of 55.1 to 51.9% over 22 days (5.8%
decrease), TPI 1020 decreased sputum neutrophils from
50.8 to 33.4% over 22 days (35.8% decrease). Whilst in those
patients with normal neutrophils at baseline, neither
budesonide nor TPI 1020 decreased sputum neutrophils
(changes were from a mean of 4.25 to 3.95% for budesonide
and from 11.5 to 17.9% over 22 days for TPI 1020). In
addition, for patients with high neutrophils at baseline, TPI
1020 decreased sputum neutrophils to <30% in most (57.1%)
patients, whilst for none of the patients treated with
budesonide were neutrophils decreased to <30%.
There were no differences for the effects of TPI 1020
versus budesonide on other cells (%) or total cells. Total
cells went from 1.1 (1.0) at baseline to 1.2 (1.1)  106 cells
on day 22 in budesonide-treated patients and from 0.7 (0.5)
to 0.8 (0.5)  106 cells in TPI 1020-treated patients.
Exploratory assessment of efficacy
The effects of TPI 1020 and budesonide on airway function,
symptoms and inflammatory parameters are presented in
Tables 2A and 2B, respectively. Therewas no improvement in
FEV1 in both groups over the 3-week period. Morning PEF,
rescue medication-free days, doses of rescue medication,
PC20, and the ACSS score improved to a similar extent in the
budesonide and the TPI 1020 groups. Sputum eosinophils,
blood eosinophils and eNO tended to be higher at baseline in
the TPI 1020 group but improved to the same extent as in the
budesonide group. Blood lymphocytes increased in budeso-
nide-treated patients, a difference that was significant
when compared to TPI 1020-treated patients (p < 0.05).0
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Figure 3 Effects of budesonide and TPI 1020 on sputum neutrophils. The effects of budesonide or TPI 1020 on percent sputum
neutrophils are presented on day 0 prior to therapy, and day 22 (end of therapy). Median values in budesonide-treated groups are
39.6 and 41.1 for day 0 and day 22, respectively, whereas median values at day 0 and day 22 in TPI 1020 group are 29.75 and 20.1,
respectively. Values connected with a solid line indicate patients with basal level of sputum neutrophils greater than 20%, and
a dashed line indicate those with baseline of sputum neutrophils less than 20% (pZ NS).
Safety PK and PD of TPI 1020 in Smokers with Asthma 1163Plasma CRP decreased more in TPI 1020-treated patients
on day 15 versus baseline (increase by 0.7 in budesonide
group versus decrease by 1.4 mg/L in TPI 1020 group,
pZ 0.03). On day 22, CRP levels were not significantly
different between groups (pZ 0.09), one patient in the TPI
1020 group having an 8.5-fold increase in the CRP level
attributed to a viral infection without an exacerbation of
asthma. When compared to baseline, 22 days of therapyTable 2A Efficacy: physiology and symptoms.
Budesonide (SD) TPI 1020 (SD)
FEV1 (ITT, L)
Baseline 3.3 (0.8) 3.0 (0.5)
Day 22 3.3 (0.8) 3.0 (0.5)
FEV1 (PD, L)
Baseline 3.2 (0.7) 3.0 (0.6)
Day 1 3.1 (0.6) 2.8 (0.6)
Day 14 3.3 (0.7) 3.0 (0.6)
Day 15 3.3 (0.7) 2.8 (0.7)
Day 22 3.3 (0.7) 3.0 (0.6)
PEF (AM, L/min)
Baseline 405.5 (91) 365.1 (93)
Day 22 423.4 (89.5) 373.5 (97)
Rescue free
days (%)
Baseline 40.9 (41) 39 (39)
Day 22 68.4 (32) 63.5 (33)
Doses of Rescue
Medication (puffs)
Baseline 17 (15) 14.7 (11)
Day 22 3.5 (4) 3.9 (4.5)
PC20 (mg/ml)
Baseline 1.4 (1.3) 3.5 (5.7)
Day 22 2.0 (1.6) 4.0 (8.9)
ACSS
Baseline 73.1 (14) 65 (11.1)
Day 22 82.4 (8.4) 71.5 (16.3)
SD, standard deviation; FEV1, forced expiratory volume in 1 s;
ITT, intent to treat; L, litre; PD, pharmacodynamic group; ACSS,
asthma control scoring system; PEF AM, peak expiratory flow in
the morning; PC20, provocative concentration that causes
a 20%. pZ NS between both groups for all values.decreased CRP in 33.2% of patients in the budesonide group
and 69.2% of patients in the TPI 1020 group.
Pharmacodynamic activity
Theeffects of lowdose TPI 1020 and budesonide on FEV1 over
an 8 h period on days 1 and 14 are presented in Fig. 4. TPI
1020, at the lowest dose studied, had no acute effects on
FEV1 on both days when compared to budesonide.
Pharmacokinetic activity
TPI 1020 was not detected in the plasma of treated subjects
at all timepoints assessed over an8 hperiod ondays 1 and14,
and on day 22, approximately 12 h after the last dose. The
budesonide plasma phamacokinetic analysis was different in
the TPI 1020 group when compared to the budesonide groupTable 2B Efficacy: inflammatory parameters.
Budesonide (SD) TPI 1020 (SD)
eNO (ppb)
Baseline 19 (17.6) 29 (27)
Day 22 9.8 (7.6) 16.9 (14)
Sputum eosinophils (%)
Baseline 2.4 (3.3) 8.7 (10.8)
Day 22 1.0 (1.0) 3.3 (4.0)
Blood eosinophils (%)
Baseline 2.3 (2.3) 2.8 (2.7)
Day 22 2.1 (1.6) 1.8 (1.7)
Blood lymphocytes (%)
Baseline 14.9 (13) 20.3 (16.6)
Day 22 22.5 (15.8) 18.4 (15.5)*
CRP (mg/L)
Baseline 2.7 (4.3) 3.6 (3.9)
Day 22 2.5 (1.4) 3.0 (4.5)
Baseline and day 22 levels in budesonide and TPI 1020-treated
patients. Change in % blood lymphocytes over time in budeso-
nide-treated patients as compared to change in TPI 1020-
treated patients, *p < 0.05, for all other comparisons the p
were NS. SD, standard deviation; eNO, exhaled nitric oxide;
CRP, C-reactive protein.
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Figure 4 Acute effects of budesonide and TPI 1020 on FEV1.
The acute effects of budesonide (400 mcg, nZ 10, repre-
sented by open symbols) and TPI 1020 (600 mcg, nZ 8, rep-
resented by closed symbols) on the FEV1 over an 8 h period are
presented for day 1 (solid line) and day 14 (dashed line)
(pZ NS TPI 1020 versus budesonide).
1164 L.-P. Boulet et al.(see Fig. 5). The median values of Cmax (pg ml1), Tmax (h)
and AUC (pg mL1 h) were on day 1: 94.1, 3.0, 350.7 and on
day 14: 95.2, 3.0, 342.6 for the TPI 1020 group versus on day
1: 562.5, 0.5, 1575.0 and on day 14: 490.1, 0.5, 1882.0 for the
budesonide-treated group.
Discussion
In this study we found that TPI 1020 is safe in patients with
asthma and has similar effects as equivalent doses of
budesonide on FEV1, PEF, PC20, use of rescue medication,
eNO and eosinophilic inflammation. TPI 1020 had additional
beneficial effects, possibly attributable to NO, on sputum
neutrophils and plasma CRP, lower systemic budesonide-1 0 1 2 3 4 5 6 7 8
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Figure 5 Pharmacokinetics of plasma budesonide. Plasma
budesonide was measured over an 8 h period in budesonide
(400 mcg, nZ 10, open symbols) and TPI 1020 (600 mcg,
nZ 8, closed symbols) treated patients after the first dose
(day 1, dashed line) and day 14 (solid line) p < 0.05 TPI 1020
versus budesonide at every time point except 0 and 8 h.exposure and lack of effect on 24 h urinary free cortisol. TPI
1020 may therefore be considered a potential drug candi-
date, not only for the treatment of allergic airway inflam-
mation often associated with an eosinophil type of
inflammation, but also for diseases where neutrophils and
systemic inflammation can play a role.
Asthma is characterized by increased airway inflamma-
tion and elevated levels of exhaled NO.2,15,16 Furthermore,
when asthma becomes controlled with corticosteroid
therapy, eNO often decreases to a level similar to that in
normal individuals.3 These results have led to speculation
that NO is negatively influencing the ongoing inflammation
within the airways of patients with asthma. However, NO
has been shown to have additional beneficial effects, such
as anti-viral and anti-bacterial properties,17e19 and causes
bronchodilation in patients with asthma.5,6 Over-expression
of eNO is beneficial in a mouse model of allergic airway
inflammation.20 We assessed whether TPI 1020, a cortico-
steroid linked to an NO donor, would be safe in asthma. We
chose smokers with asthma since this would also allow us to
assess whether TPI 1020 would affect sputum neutrophils in
these patients. All subjects were current smokers with
a smoking history that was insufficient to induce clinically
significant COPD.
TPI 1020 was safe in patients with asthma over the
3 weeks of administration, even at a dose that would be
clinically equivalent to 1600 mcg of budesonide per day.
With TPI 1020, we found a three-fold reduction in treat-
ment-emergent adverse events and less adverse events
that were considered by the investigator to be drug-
related, TPI 1020 may thus be advantageous over other
inhaled corticosteroids at high doses.21e24
One of the measures that have been shown to help
assess systemic absorption and potential long term toxicity
of corticosteroids is the 24 h urinary free cortisol
measurement25 (UFC). A dose-response relationship
between the dose of budesonide administered and UFC has
been reported.23 In this study we have confirmed that
1600 mcg of budesonide per day decreases UFC signifi-
cantly. TPI 1020 had no significant effect on UFC at a dose
of 2400 mcg per day. More studies are needed to under-
stand the absorption, metabolism and distribution of TPI
1020 in humans, but the absence of effect of TPI 1020 on
UFC may be related to the different plasma PK profile of
budesonide in both treatment groups. Indeed, the Cmax
and AUC of plasma budesonide were more than five-fold
lower in the TPI 1020 group than in the corresponding
budesonide group. It could thus be expected that less
systemic exposure would translate to less effects on the
adrenalepituitary axis.
Although this study was designed to assess safety, we
did perform common measures associated with efficacy.
This study was not powered for any of the standard
measures of efficacy and results should be considered
exploratory. In addition, the length of the study was not
sufficient to determine the maximal effects of the corti-
costeroids. However, TPI 1020 seemed to have the same
trends in effects on FEV1, PEF, days with rescue medica-
tion usage, the amount of rescue medication employed,
asthma control score, methacholine response, sputum
eosinophils and exhaled NO. It is interesting that TPI 1020
decreased eNO to a similar extent as the equimolar
Safety PK and PD of TPI 1020 in Smokers with Asthma 1165amount of budesonide (12.1 versus 9.2 ppb decrease with
TPI 1020 versus budesonide, respectively). These results
would suggest that the amount of NO released by TPI 1020
within the lungs is not sufficient to affect eNO or that the
NO released is metabolized prior to its passage into the
airways.
We also assessed whether TPI 1020, or the NO that it
releases, would have additional pharmacological effects
within the lungs. NO has been shown to inhibit neutrophil
recruitment4,8 and TPI 1020 inhibited the recruitment of
neutrophils into the lungs of a guinea pig model of LPS-
induced lung inflammation, whilst budesonide was
without effect in this model.8 In our study, TPI 1020
decreased neutrophils in the sputum of patients with
asthma after 22 days by 32.6%, whereas budesonide had
no effect. Although we had powered the study for a 20%
difference in sputum neutrophils between groups, the
difference observed was not significant. We believe
that this could be explained by the unexpectedly large
number of patients with normal neutrophils at baseline in
the TPI 1020-treated patients. Indeed, 6 of 13 TPI 1020-
treated patients had sputum neutrophils at baseline
below 20%. The finding that not all asthmatic smokers
have increased neutrophils in their sputum is consistent
with the results recently reported by Lazarus et al.26
in mild asthmatic smokers. Interestingly, the decrease in
sputum neutrophils caused by TPI 1020 occurred only
in patients with high neutrophils at baseline suggesting
that TPI 1020 is acting on the mechanism by which ciga-
rette smoke recruits neutrophils into the airways, and not
on the normal homeostatic mechanism of neutrophil
recruitment.
Increased plasma CRP has been associated with
increased mortality in patients with cardiovascular diseases
and with COPD.27 There is a controversy on whether inhaled
corticosteroids decrease CRP in patients with COPD.28
Although there was high variability in CRP results, TPI 1020
decreased CRP more than budesonide, a finding that would
need to be reproduced in larger studies. These effects may
be caused by the additional anti-inflammatory effects of
NO on chemokines and cytokines.
Conclusions
This study showed that TPI 1020 was safe in patients with
asthma. In addition to having similar efficacy effects as
budesonide on asthma, TPI 1020 had an improved PK profile
with no effects on UFC, and additional effects on sputum
neutrophils and plasma CRP. These observations suggest
that this new agent may be considered as a novel thera-
peutic option for airways diseases where increased
neutrophils and systemic inflammation play a role.
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